The 2006 AHA/ASA guidelines for primary prevention of atherosclerotic events recommend that aspirin should be used long-term in people with a 10-year risk of cardiovascular events ≥6-10% to prevent a first cardiovascular event (Class I recommendation, Level A evidence). According to the trial meta- and guidelines, combined with the Cardiovascular Disease Risk Assessment Scale, aspirin should be considered in the following three categories of hypertensive patients if there are no contraindications: 1. People over 50 years of age with simple hypertension, with well-controlled blood pressure and no contraindications; 2. People under 50 years of age with hypertension combined with any of the risk factors, with well-controlled blood pressure and no contraindications; 3. People with thrombotic disease (coronary artery disease, cerebral infarction, and peripheral artery disease) in hypertensive patients with no contraindications and good blood pressure control. Risk factors include: smoking, diabetes mellitus, hyperlipidemia, abdominal obesity, family history of coronary heart disease, etc. Because the effect of aspirin is platelet thromboxane A2 production and the average lifespan of platelets is 10 days, the inhibitory effect on platelets disappears after a period of discontinuation of aspirin, and prevention of cardiovascular events in hypertensive patients is a lifelong process, so aspirin should be taken for life as long as there are no contraindications. The American Heart Association guidelines for hypertension recommend indefinite use of aspirin; the European guidelines for hypertension recommend lifelong use of aspirin. Please refer to your physician’s instructions for specific medications.